Published in Cell Rep on September 18, 2014
RUNX1B Expression Is Highly Heterogeneous and Distinguishes Megakaryocytic and Erythroid Lineage Fate in Adult Mouse Hematopoiesis. PLoS Genet (2016) 1.42
Dynamic Gene Regulatory Networks Drive Hematopoietic Specification and Differentiation. Dev Cell (2016) 0.96
UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO. Leukemia (2015) 0.86
An autonomous CEBPA enhancer specific for myeloid-lineage priming and neutrophilic differentiation. Blood (2016) 0.85
Chronic FLT3-ITD Signaling in Acute Myeloid Leukemia Is Connected to a Specific Chromatin Signature. Cell Rep (2015) 0.83
Genome-wide co-occupancy of AML1-ETO and N-CoR defines the t(8;21) AML signature in leukemic cells. BMC Genomics (2015) 0.80
RUNX1/ETO blocks selectin-mediated adhesion via epigenetic silencing of PSGL-1. Oncogenesis (2015) 0.78
Genome-wide repression of eRNA and target gene loci by the ETV6-RUNX1 fusion in acute leukemia. Genome Res (2016) 0.77
Genome-scale definition of the transcriptional programme associated with compromised PU.1 activity in acute myeloid leukaemia. Leukemia (2015) 0.76
Developmental-stage-dependent transcriptional response to leukaemic oncogene expression. Nat Commun (2015) 0.76
The leukemia-associated RUNX1/ETO oncoprotein confers a mutator phenotype. Leukemia (2015) 0.76
MiR144/451 Expression Is Repressed by RUNX1 During Megakaryopoiesis and Disturbed by RUNX1/ETO. PLoS Genet (2016) 0.75
The multifaceted functions of C/EBPα in normal and malignant haematopoiesis. Leukemia (2015) 0.75
Role of RUNX1 in hematological malignancies. Blood (2017) 0.75
High-Resolution Mapping of RNA Polymerases Identifies Mechanisms of Sensitivity and Resistance to BET Inhibitors in t(8;21) AML. Cell Rep (2016) 0.75
Understanding transcriptional regulatory networks using computational models. Curr Opin Genet Dev (2016) 0.75
New insights into transcriptional and leukemogenic mechanisms of AML1-ETO and E2A fusion proteins. Front Biol (Beijing) (2016) 0.75
Genome Wide Mapping of NR4A Binding Reveals Cooperativity with ETS Factors to Promote Epigenetic Activation of Distal Enhancers in Acute Myeloid Leukemia Cells. PLoS One (2016) 0.75
The LMO2 -25 Region Harbours GATA2-Dependent Myeloid Enhancer and RUNX-Dependent T-Lymphoid Repressor Activity. PLoS One (2015) 0.75
ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia. Nat Commun (2017) 0.75
A FOXO1-induced oncogenic network defines the AML1-ETO pre-leukemic program. Blood (2017) 0.75
Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell (2010) 23.97
Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med (2004) 11.61
Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science (1994) 7.60
Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci U S A (1997) 5.44
Differential requirements for Runx proteins in CD4 repression and epigenetic silencing during T lymphocyte development. Cell (2002) 5.07
Combinatorial transcriptional control in blood stem/progenitor cells: genome-wide analysis of ten major transcriptional regulators. Cell Stem Cell (2010) 5.05
Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet (2001) 4.79
Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP alpha. Immunity (2004) 3.84
ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci U S A (1998) 3.59
AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat Med (2001) 3.47
Transcriptional repression by AML1 and LEF-1 is mediated by the TLE/Groucho corepressors. Proc Natl Acad Sci U S A (1998) 3.07
The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J (1993) 3.00
Emerging properties of animal gene regulatory networks. Nature (2010) 2.89
Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood (2002) 2.71
ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain. Mol Cell Biol (2001) 2.60
Genome-wide analysis of simultaneous GATA1/2, RUNX1, FLI1, and SCL binding in megakaryocytes identifies hematopoietic regulators. Dev Cell (2011) 2.30
RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol (2011) 2.11
Interaction and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid cell differentiation. EMBO J (1998) 2.09
The tetramer structure of the Nervy homology two domain, NHR2, is critical for AML1/ETO's activity. Cancer Cell (2006) 2.09
Sox4 is a key oncogenic target in C/EBPα mutant acute myeloid leukemia. Cancer Cell (2013) 1.89
Genome-wide analysis of estrogen receptor alpha DNA binding and tethering mechanisms identifies Runx1 as a novel tethering factor in receptor-mediated transcriptional activation. Mol Cell Biol (2010) 1.75
The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia. Blood (2002) 1.58
The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. Science (2011) 1.49
The genomic landscapes of inflammation. Genes Dev (2011) 1.45
Two distinct auto-regulatory loops operate at the PU.1 locus in B cells and myeloid cells. Blood (2011) 1.41
RUNX1 reshapes the epigenetic landscape at the onset of haematopoiesis. EMBO J (2012) 1.37
Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding. Leukemia (2012) 1.35
AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells. Blood (2002) 1.34
Wellington: a novel method for the accurate identification of digital genomic footprints from DNase-seq data. Nucleic Acids Res (2013) 1.33
The RUNX family in breast cancer: relationships with estrogen signaling. Oncogene (2012) 1.30
ERG dependence distinguishes developmental control of hematopoietic stem cell maintenance from hematopoietic specification. Genes Dev (2011) 1.30
Defining a tissue stem cell-driven Runx1/Stat3 signalling axis in epithelial cancer. EMBO J (2012) 1.25
The t(8;21) chromosomal translocation in acute myelogenous leukemia modifies intranuclear targeting of the AML1/CBFalpha2 transcription factor. Proc Natl Acad Sci U S A (1999) 1.24
Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2. Genes Chromosomes Cancer (2003) 1.24
Addiction of t(8;21) and inv(16) acute myeloid leukemia to native RUNX1. Cell Rep (2013) 1.22
Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells. J Clin Invest (2013) 1.20
Developmentally regulated recruitment of transcription factors and chromatin modification activities to chicken lysozyme cis-regulatory elements in vivo. Mol Cell Biol (2003) 1.15
Epigenetic consequences of AML1-ETO action at the human c-FMS locus. EMBO J (2003) 1.14
ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia. Blood (2012) 1.12
RUNX1 associates with histone deacetylases and SUV39H1 to repress transcription. Oncogene (2006) 1.11
Sustained PU.1 levels balance cell-cycle regulators to prevent exhaustion of adult hematopoietic stem cells. Mol Cell (2013) 1.09
siRNA-mediated AML1/MTG8 depletion affects differentiation and proliferation-associated gene expression in t(8;21)-positive cell lines and primary AML blasts. Oncogene (2006) 1.05
Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukemia. Blood (2013) 1.04
Chromatin accessibility, p300, and histone acetylation define PML-RARα and AML1-ETO binding sites in acute myeloid leukemia. Blood (2012) 1.02
CBFB-MYH11/RUNX1 together with a compendium of hematopoietic regulators, chromatin modifiers and basal transcription factors occupies self-renewal genes in inv(16) acute myeloid leukemia. Leukemia (2013) 1.02
New insights into the role of Runx1 in epithelial stem cell biology and pathology. J Cell Biochem (2013) 0.99
A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis. Nature (2013) 0.99
Gene regulatory networks governing haematopoietic stem cell development and identity. Int J Dev Biol (2010) 0.97
Homing and invasiveness of MLL/ENL leukemic cells is regulated by MEF2C. Blood (2009) 0.93
The oncogenic fusion protein RUNX1-CBFA2T1 supports proliferation and inhibits senescence in t(8;21)-positive leukaemic cells. BMC Cancer (2004) 0.92
Expansion of functionally defined mouse hematopoietic stem and progenitor cells by a short isoform of RUNX1/AML1. Blood (2011) 0.91
A novel complex, RUNX1-MYEF2, represses hematopoietic genes in erythroid cells. Mol Cell Biol (2012) 0.88
Transient depletion of RUNX1/RUNX1T1 by RNA interference delays tumour formation in vivo. Leukemia (2008) 0.85
Hematopoietic transcriptional mechanisms: from locus-specific to genome-wide vantage points. Exp Hematol (2014) 0.84